COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00392665
Recruitment Status : Terminated (slow accrual)
First Posted : October 26, 2006
Results First Posted : March 14, 2017
Last Update Posted : April 13, 2017
Dana-Farber Cancer Institute
Emory University
University of North Carolina, Chapel Hill
Genentech, Inc.
OSI Pharmaceuticals
Information provided by (Responsible Party):
Lori J. Wirth, MD, Massachusetts General Hospital

Brief Summary:
The main purpose of this research study is to collect information to learn how effective erlotinib (tarceva) is in combination with either bevacizumab or sulindac in treating patients with squamous cell carcinoma of the head and neck. Erlotinib and bevacizumab are targeted therapy drugs that can control tumor growth by targeting specific abnormalities sometimes found on cancer cells. Erlotinib targets epidermal growth factor receptor (EGFR), and bevacizumab targets vascular endothelial growth factor (VEGF). Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that can block G protein-coupled receptor which laboratory evidence shows is associated with both cancer cell growth and EGFR activity. The bevacizumab being administered in this study is not a commercially marketed formulation of the drug. Previous research with head and neck cancer suggest that erlotinib alone has some anti-cancer activity. This research study is designed to see how well erlotinib works in combination with bevacizumab or sulindac in head and neck cancer.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of the Head and Neck (SCCHN) Drug: Bevacizumab Drug: erlotinib Drug: Sulindac Phase 2

Detailed Description:
  • Participants will be randomized to either Arm A: erlotinib plus bevacizumab, or Arm B: erlotinib plus sulindac. Participants will have an equal chance of being placed in any group.
  • Medication on Arm A: erlotinib plus bevacizumab: Participants will take erlotinib pills orally once a day. Bevacizumab will be given intravenously on day one of each treatment cycle (each treatment cycle will last three weeks). Urine tests will be performed once every three weeks to test kidney function.
  • Medication on Arm B: erlotinib plus sulindac: Participants will take erlotinib pills orally once a day. Sulindac will be taken orally twice a day.
  • Physical exams will be performed during each treatment cycle and will include vital signs and general health questions. We will take the participants blood pressure every 2 weeks for the first 6 weeks. After that point, we will take it every 3 weeks or more often if necessary. Blood tests will be performed including chemistry and hematology.
  • After every 2 cycles, a repeat CT scan, MRI, and/or PET scan will be performed along with either a chest x-ray or CT scan to ensure that there is no tumor in the participants lungs. We may also do a bone scan if there may be tumor in the participants bones, and abdominal CT scan if there may be tumor in the liver, and a head CT scan or MRI if there may be tumor in the brain.
  • After the final treatment the participant will be seen in the clinic to see if they have had any side effects from the drugs within 30 days of stopping the drugs.
  • Participants will be in this research study for as long as they are receiving clinical benefits from the study drugs, and do not develop excessive side effects or disease progression. After treatment is discontinued, we will follow the participant closely for 30 days and every 1-2 months after that.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Study of Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Study Start Date : October 2006
Actual Primary Completion Date : August 2012
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Active Comparator: Erlotinib + Bevacizumab
erlotinib plus bevacizumab
Drug: Bevacizumab
Given intravenously on day one of each 3 week cycle

Drug: erlotinib
Given orally once a day
Other Name: Tarceva

Active Comparator: Erlotinib + Sulindac
erlotinib plus sulindac
Drug: erlotinib
Given orally once a day
Other Name: Tarceva

Drug: Sulindac
Given orally twice a day

Primary Outcome Measures :
  1. Efficacy of Erlotinib Plus Bevacizumab (Arm A) or Erlotinib Plus Sulindac (Arm B) as Measured by Progression-free Survival. [ Time Frame: 1 year ]
    The primary outcome will be measured by median progression-free survival (PFS), determined by the Kaplan-Meier method for both Arm A and Arm B. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Secondary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: 2 years ]

    Overall response rate (complete plus partial response=ORR), as determined by RECIST.

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

  2. Duration of Overall Survival [ Time Frame: 2 years ]
    Median overall survival (OS), determined by the Kaplan-Meier method.

  3. Number of Participants With Toxicities According to Severity [ Time Frame: 2 years ]
    Toxicities by Grades 1 or 2 and Grades 3 or 4 in each arm. Grade 4 = life-threatening, Grade 3 = serious, Grade 2 = moderate, Grade 1 = Mild

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically/cytologically documented SCCHN, excluding salivary gland primary sites
  • 18 years of age or older
  • Have evaluable locoregional and/or metastatic disease according to RECIST that is not appropriate for treatment by primary surgical resection or radiotherapy
  • Have locoregional and/or metastatic disease that has failed to respond to or relapsed from at least one prior chemotherapy or chemoradiotherapy
  • Life expectancy of at least 4 months
  • ECOG performance status of 0-2
  • Use of effective means of contraception in patients of child-bearing potential

Exclusion Criteria:

  • Other malignancy within 5 years except non-melanomatous skin cancer, or carcinoma in situ of the cervix, bladder or head and neck
  • Concurrent anticancer therapy other than that of this study
  • Treatment with any anticancer drug within 28 days of day 1
  • Radiotherapy within 28 days of day 1
  • Any unresolved toxicity greater than NCI-CTCAE v 3.0 grade 2 from prior systemic anticancer therapy
  • Any prior therapy that targets the ErbB and/or VEGF pathways
  • Concurrent therapy with any NSAID
  • Known hypersensitivity characterized by acute bronchospasm, urticaria and/or rhinitis to NSAIDs, including aspirin
  • Serum creatinine > 1.5 x ULN
  • Abnormal LFTs as outlined in protocol
  • Blood pressure > 150/100mmHg
  • Active unstable angina, or myocardial infarction within 6 months
  • NYHA Grade II or greater congestive heart failure
  • History of stroke within 6 months
  • Clinically significant active peripheral vascular disease
  • Absolute neutrophil count < 1000/mm3 or platelets < 100,000/mm3
  • Evidence of bleeding diathesis or coagulopathy.
  • Tumor encasing the carotid artery, or other major vessel that in the opinion of the investigators is at risk for tumor-related hemorrhage
  • Presence of central nervous system or brain metastases
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study
  • Minor surgical procedures such as fine needle aspiration or core biopsy within 5 days prior to day 1
  • Pregnant or lactating
  • History of abdominal fistula or intra-abdominal abscess within 6 months
  • History of gastrointestinal ulcer, perforation, or bleeding within 6 months
  • Serious non-healing wound or ulcer or active uncontrolled infection
  • Bone fracture within 28 days
  • Active substance abuse, defined by substance abuse of alcohol, cocaine or intravenous drug use within 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00392665

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Emory University
University of North Carolina, Chapel Hill
Genentech, Inc.
OSI Pharmaceuticals
Layout table for investigator information
Principal Investigator: Jochen Lorch, MD Dana-Farber Cancer Institute
Layout table for additonal information
Responsible Party: Lori J. Wirth, MD, Principal Investigator, Massachusetts General Hospital Identifier: NCT00392665    
Other Study ID Numbers: 06-111
First Posted: October 26, 2006    Key Record Dates
Results First Posted: March 14, 2017
Last Update Posted: April 13, 2017
Last Verified: March 2017
Keywords provided by Lori J. Wirth, MD, Massachusetts General Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site
Erlotinib Hydrochloride
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors